UNSPSC 51373329: Aspirin/oxycodone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373329 Aspirin/oxycodone is a Commodity code that in recent state and local solicitations covers pharmaceutical procurement, including both controlled substances and emergency medical products. State and local governments soliciting under this code are seeking to procure pain management and opioid-related medications, naloxone and drug deactivation systems for community health programs, and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements. The issuing bodies range from county health departments and state health and human services agencies to multistate cooperative purchasing alliances. Seminole County, Florida has solicited naloxone and drug deactivation systems through competitive bidding; the Texas Health and Human Services Commission has issued a Request for Information to explore direct-to-manufacturer pharmaceutical procurement models; and the Minnesota Multistate Cooperative Purchasing Alliance has solicited generic multi-source pharmaceuticals and OTC products on behalf of multiple participating state and local government facilities.

Recent procurement activity concentrates in Florida and Texas, with broader multistate participation through cooperative purchasing vehicles. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for implementing direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed to participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. All three solicitations require vendors to demonstrate compliance with FDA regulations, Good Manufacturing Practices, and Drug Supply Chain Security Act requirements, and to maintain specified insurance coverage levels.